Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase3, Multi-Center, Open-Label, Randomized, Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Insulin Inhalation Powder in Combination With Lantus® Versus Humalog® in Combination With Lantus® in Subjects With Type 1 Diabetes Mellitus Over a 16-Week Treatment Period

NCT00700622 is registered in ClinicalTrials.gov with Mannkind Corporation as lead sponsor.

NCT NCT00700622
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00700622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase3, Multi-Center, Open-Label, Randomized, Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Insulin Inhalation Powder in Combination With Lantus® Versus Humalog® in Combination With Lantus® in Subjects With Type 1 Diabetes Mellitus Over a 16-Week Treatment Period
Lead sponsor
Mannkind Corporation
Phase
Phase 3
Overall status
Terminated
Start date
May 31, 2008
Completion date
March 31, 2010
Enrollment
130 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, type 1